PMID- 24672724
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140327
LR  - 20211021
IS  - 2090-2085 (Print)
IS  - 2090-2093 (Electronic)
IS  - 2090-2093 (Linking)
VI  - 2014
DP  - 2014
TI  - Vascular endothelial growth factor and brain-derived neurotrophic factor in 
      quetiapine treated first-episode psychosis.
PG  - 719395
LID - 10.1155/2014/719395 [doi]
LID - 719395
AB  - Objective. It has been suggested that atypical antipsychotics confer their 
      effects via brain-derived neurotrophic factor (BDNF). We investigated the effect 
      of quetiapine on serum levels of BDNF and vascular endothelial growth factor 
      (VEGF) in drug-naive first-episode psychosis subjects. Methods. Fifteen patients 
      drawn from a larger study received quetiapine treatment for twelve weeks. 
      Baseline levels of serum BDNF and VEGF were compared to age- and sex-matched 
      healthy controls and to levels following treatment. Linear regression analyses 
      were performed to determine the relationship of BDNF and VEGF levels with outcome 
      measures at baseline and week 12. Results. The mean serum BDNF level was 
      significantly higher at week 12 compared to baseline and correlated with 
      reductions in Brief Psychiatric Rating Scale (BPRS) and general psychopathology 
      scores. Changes in serum VEGF levels also correlated significantly with a 
      reduction in BPRS scores, a significant improvement in PANNS positive symptoms 
      scores, and displayed a positive relationship with changes in BDNF levels. 
      Conclusions. Our findings suggest that BDNF and VEGF are potential biomarkers for 
      gauging improvement of psychotic symptoms. This suggests a novel 
      neurotrophic-based mechanism of the drug effects of quetiapine on psychosis. This 
      is the first report of VEGF perturbation in psychosis.
FAU - Murphy, Brendan P
AU  - Murphy BP
AD  - Early in Life Mental Health Service, Southern Health, Melbourne, VIC 3175, 
      Australia ; School of Psychology and Psychiatry, Monash University, Melbourne, 
      VIC 3800, Australia.
FAU - Pang, Terence Y
AU  - Pang TY
AD  - Howard Florey Institute, Florey Neuroscience Institutes, University of Melbourne, 
      Melbourne, VIC 3052, Australia.
FAU - Hannan, Anthony J
AU  - Hannan AJ
AD  - Howard Florey Institute, Florey Neuroscience Institutes, University of Melbourne, 
      Melbourne, VIC 3052, Australia.
FAU - Proffitt, Tina-Marie
AU  - Proffitt TM
AD  - Orygen Youth Health Research Centre, University of Melbourne, Melbourne, VIC 
      3052, Australia.
FAU - McConchie, Mirabel
AU  - McConchie M
AD  - Orygen Youth Health Research Centre, University of Melbourne, Melbourne, VIC 
      3052, Australia.
FAU - Kerr, Melissa
AU  - Kerr M
AD  - Orygen Youth Health Research Centre, University of Melbourne, Melbourne, VIC 
      3052, Australia.
FAU - Markulev, Connie
AU  - Markulev C
AD  - Orygen Youth Health Research Centre, University of Melbourne, Melbourne, VIC 
      3052, Australia.
FAU - O'Donnell, Colin
AU  - O'Donnell C
AD  - St. Davnet's Hospital, Monaghan, County Monaghan, Ireland.
FAU - McGorry, Patrick D
AU  - McGorry PD
AD  - Orygen Youth Health Research Centre, University of Melbourne, Melbourne, VIC 
      3052, Australia.
FAU - Berger, Gregor E
AU  - Berger GE
AD  - Department of Child and Adolescent Psychiatry, University of Zurich, 8032 Zurich, 
      Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20140205
PL  - Egypt
TA  - Schizophr Res Treatment
JT  - Schizophrenia research and treatment
JID - 101576450
PMC - PMC3941155
EDAT- 2014/03/29 06:00
MHDA- 2014/03/29 06:01
PMCR- 2014/02/05
CRDT- 2014/03/28 06:00
PHST- 2013/08/10 00:00 [received]
PHST- 2013/10/07 00:00 [revised]
PHST- 2013/10/14 00:00 [accepted]
PHST- 2014/03/28 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2014/03/29 06:01 [medline]
PHST- 2014/02/05 00:00 [pmc-release]
AID - 10.1155/2014/719395 [doi]
PST - ppublish
SO  - Schizophr Res Treatment. 2014;2014:719395. doi: 10.1155/2014/719395. Epub 2014 
      Feb 5.